Health ❯ Healthcare ❯ Pharmaceuticals ❯ Cancer Treatment

Bladder Cancer

EMA Validates Astellas Bid to Add Padcev–Keytruda Combo for Perioperative Muscle-Invasive Bladder Cancer

The review opens a path to an EU decision based on Phase 3 data showing higher complete responses versus standard chemotherapy.

Securities Class Action Filed Against ImmunityBio After FDA Flags Anktiva Marketing

FDA Warns ImmunityBio Over Anktiva Ads, Citing Misleading Cancer Claims

EU Grants Conditional Approval for ImmunityBio’s Anktiva in BCG‑Unresponsive Bladder Cancer

ImmunityBio Rallies as Anktiva Sales Surge 700% and Registrational Trial Passes 85% Enrollment

FDA Approves Perioperative Keytruda–Padcev for Cisplatin‑Ineligible Muscle‑Invasive Bladder Cancer

FDA Approves J&J’s Inlexzo Bladder Drug-Delivery Device for BCG‑Unresponsive NMIBC